Rapport Therapeutics (RAPP) Stock Analysis
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Rapport Therapeutics (RAPP) trades at $47.85 with AI Score 24/100 (Grade F). Rapport Therapeutics is a clinical-stage biopharmaceutical company focused on developing small molecule medicines for central nervous system (CNS) disorders. Market cap: $2.29B, Sector: Healthcare.
Price as of Aug 21, 2026 · Last analyzed: May 10, 2026RAPP stock analysis for 2026: Analysts have set a consensus price target of $52.22 for Rapport Therapeutics, suggesting 9.1% upside from the current price of $47.85. The AI MoonshotScore is 24/100, indicating a strong bearish outlook. Key factors: analyst coverage, AI-driven quantitative scoring.
RAPP: 3/3 scored disciplines lean bearish. Dominant signal: Seth Klarman bearish.
How is this calculated? →Why this analysis is different
- A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
- An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
- Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.
Rapport Therapeutics (RAPP) Healthcare & Pipeline Overview
Rapport Therapeutics, a clinical-stage biopharmaceutical company, is focused on pioneering small molecule medicines for central nervous system disorders. Their lead candidate, RAP-219, targets focal epilepsy, positioning them in a high-growth area of unmet medical need within the biotechnology sector.
What Is the Investment Thesis for RAPP?
Rapport Therapeutics presents a notable research candidate within the biotechnology sector, driven by its focus on CNS disorders and its lead candidate, RAP-219. The company's innovative approach to targeting TARPy8-containing AMPARs for focal epilepsy and other CNS conditions offers significant potential. The company's robust gross margin of 97.5% indicates strong pricing power, although the negative profit margin of -536.4% reflects the high R&D expenses typical of clinical-stage biopharmaceutical companies. Upcoming clinical trial results for RAP-219 will be a key catalyst. Potential risks include clinical trial failures and competition from established pharmaceutical companies.
Based on FMP financials and quantitative analysis
RAPP Key Highlights
Market capitalization of $2.29B, reflecting investor confidence in Rapport Therapeutics' pipeline and technology.
- Gross margin of 97.5%, indicating strong potential profitability upon commercialization of products.
- Operating with 69 employees, highlighting a lean and focused operational structure.
- Lead product candidate RAP-219 targets a significant unmet need in focal epilepsy and other CNS disorders.
- Beta of 1.10, suggesting a slightly higher volatility compared to the overall market.
Who Are RAPP's Competitors?
RAPP is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| LLY Eli Lilly and Company | $1245.69 | -2.71% | $1.17T | 97 |
| ABBV AbbVie Inc. | $265.06 | -0.34% | $468B | 82 |
| JNJ Johnson & Johnson | $267.37 | -2.21% | $644B | 90 |
| ADMA ADMA Biologics, Inc. | $9.81 | -2.34% | $2.27B | 91 |
| HRMY Harmony Biosciences Holdings, Inc. | $38.32 | -4.04% | $2.22B | 98 |
| VCEL Vericel Corporation | $42.11 | -3.35% | $2.16B | 94 |
| MYOV Myovant Sciences Ltd. | $26.98 | -0.04% | $2.62B | 71 |
| GLPG Galapagos NV | $27.98 | +1.71% | $1.84B | 70 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are RAPP's Key Strengths?
Novel approach to targeting TARPy8-containing AMPARs for CNS disorders.
- Lead product candidate RAP-219 with potential for multiple indications.
- Experienced management team with expertise in drug development.
- Strong intellectual property protection for its drug candidates.
What Are RAPP's Weaknesses?
Clinical-stage company with no currently approved products.
- High R&D expenses and negative profit margin.
- Reliance on the success of its lead product candidates.
- Limited commercialization capabilities.
What Could Drive RAPP Stock Higher?
Clinical trial results for RAP-219 in focal epilepsy.
- Initiation of clinical trials for RAP-199.
- Advancement of nAChR programs for chronic pain and hearing disorders.
- Potential strategic partnerships and collaborations.
What Are the Key Risks for RAPP?
Negative return on equity (-24.8%) — the business is not currently generating profit on shareholder capital.
- Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
- Clinical trial failures and regulatory hurdles.
- Competition from established pharmaceutical companies.
- Patent expiration and generic competition.
- High R&D expenses and negative profit margin.
What Are the Growth Opportunities for RAPP?
- Expansion of RAP-219 into additional CNS indications: Rapport Therapeutics has the opportunity to expand the application of RAP-219 beyond focal epilepsy to other CNS disorders, such as peripheral neuropathic pain and bipolar disorder. These indications represent significant market opportunities, with the global neuropathic pain market projected to reach $8.3 billion by 2027. Successful clinical trials in these areas could significantly increase the value of RAP-219.
- Advancement of RAP-199: The development of RAP-199, a TARPy8 targeted molecule with differentiated chemical and pharmacokinetic properties, presents another growth opportunity. This molecule could offer improved efficacy or safety compared to RAP-219, potentially capturing a larger share of the focal epilepsy market. Clinical trials for RAP-199 are expected to commence in 2027, providing a near-term catalyst for growth.
- Development of nicotinic acetylcholine receptor (nAChR) programs: Rapport Therapeutics' nAChR programs, including a6 nAChR for chronic pain and a9a10 nAChR for hearing disorders, represent long-term growth opportunities. The chronic pain market is substantial, with a global value of $76.7 billion in 2023. Success in these programs could diversify Rapport Therapeutics' pipeline and revenue streams.
- Strategic partnerships and collaborations: Rapport Therapeutics can pursue strategic partnerships and collaborations with larger pharmaceutical companies to accelerate the development and commercialization of its product candidates. These partnerships could provide access to additional funding, expertise, and market reach, enhancing the company's growth prospects. Potential partners include companies specializing in CNS therapeutics or pain management.
- Acquisition or licensing of complementary technologies: Rapport Therapeutics could acquire or license complementary technologies to expand its pipeline and enhance its competitive position. This could include technologies targeting other CNS disorders or platforms for drug delivery. Such acquisitions could provide synergies and accelerate the company's growth trajectory. The company may consider assets that can be integrated within the next 2-3 years.
What Are RAPP's Competitive Advantages?
- Proprietary small molecule medicines targeting CNS disorders.
- Novel approach to targeting TARPy8-containing AMPARs.
- Strong intellectual property protection for its drug candidates.
- Experienced management team with expertise in drug development.
What Does RAPP Do?
Rapport Therapeutics, Inc., founded in 2022 and based in Boston, Massachusetts, is a clinical-stage biopharmaceutical company dedicated to discovering and developing transformational small molecule medicines for patients suffering from central nervous system (CNS) disorders. Formerly known as Precision Neuroscience NewCo, Inc., the company rebranded to Rapport Therapeutics in October 2022, signaling a refined focus on CNS therapeutics. Their lead product candidate, RAP-219, is an investigational small molecule designed to inhibit TARPy8-containing AMPARs with picomolar affinity. This mechanism is being explored for the treatment of focal epilepsy and potentially other CNS disorders, including peripheral neuropathic pain and bipolar disorder. In addition to RAP-219, Rapport Therapeutics is developing RAP-199, a TARPy8 targeted molecule with differentiated chemical and pharmacokinetic properties. The company also has nicotinic acetylcholine receptor (nAChR) programs, including a6 nAChR to treat chronic pain and a9a10 nAChR for the treatment of hearing disorders. Rapport Therapeutics is committed to addressing significant unmet needs in CNS disorders through innovative small molecule therapeutics.
What Products and Services Does RAPP Offer?
- Discover and develop small molecule medicines for central nervous system (CNS) disorders.
- Focus on transformational therapies for patients suffering from neurological conditions.
- Develop RAP-219, an investigational small molecule for the treatment of focal epilepsy.
- Target TARPy8-containing AMPARs with picomolar affinity.
- Develop RAP-199, a TARPy8 targeted molecule with differentiated properties.
- Develop nicotinic acetylcholine receptor (nAChR) programs for chronic pain and hearing disorders.
How Does RAPP Make Money?
- Develop and commercialize small molecule therapeutics for CNS disorders.
- Generate revenue through the sale of approved drugs.
- Potentially generate revenue through licensing agreements and partnerships.
- Focus on intellectual property protection for its drug candidates.
What Industry Does RAPP Operate In?
Rapport Therapeutics operates within the biotechnology industry, which is characterized by high growth potential and significant investment in research and development. The CNS therapeutics market is a substantial segment within the pharmaceutical industry, driven by the increasing prevalence of neurological disorders and the demand for innovative treatments. Rapport Therapeutics competes with other biotechnology and pharmaceutical companies developing therapies for CNS disorders. The company's focus on small molecule medicines and its novel approach to targeting TARPy8-containing AMPARs differentiate it within the competitive landscape.
Who Are RAPP's Key Customers?
- Patients suffering from central nervous system (CNS) disorders, such as focal epilepsy, peripheral neuropathic pain, and bipolar disorder.
- Healthcare providers who prescribe and administer the company's drugs.
- Hospitals and clinics that utilize the company's therapies.
- Pharmaceutical companies that may partner with or acquire Rapport Therapeutics.
Key Financial Metrics
Return on equity for Rapport Therapeutics stands at -24.8%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -21.6%, showing how much profit it generates from its asset base. Its free cash flow yield is -5.7%, a gauge of the cash the business throws off relative to its market value. A current ratio of 27.08 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -5.8%, the inverse of the P/E and a quick read on earnings relative to price.
Rapport Therapeutics (RAPP) Valuation Context
Valued at $2.29B, RAPP is classified as a mid-cap stock. Relative to its peer group, RAPP's quantitative score of 24/100 is below the peer average of 92/100.
Company Profile
Rapport Therapeutics operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Boston, US. The company is led by CEO Abraham N. Ceesay. RAPP has traded publicly since 2024.
Financial Health
Rapport Therapeutics's Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of 38.17 places it in the safe zone, indicating low near-term bankruptcy risk.
Forward Outlook
Wall Street analysts project Rapport Therapeutics revenue of about $20.0M for fiscal 2026, with EPS near $-4.04. The estimate reflects 10 contributing analysts.
RAPP Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- Recent insider buying suggests confidence in the company's pipeline, indicating a belief in upcoming successes.
- Community sentiment has shifted positively, with discussions highlighting the potential of their innovative therapies.
- Analysts are optimistic about the company's recent partnerships, which could enhance their research capabilities and market reach.
- New clinical trial results have sparked interest, suggesting that Rapport's therapies may address unmet medical needs effectively.
Bear Case
- Concerns over regulatory hurdles persist, with some investors wary of potential delays in product approvals.
- Community discussions reveal skepticism about the company's ability to scale production efficiently, which could impact future growth.
- Recent market developments have raised questions about competition, as other firms are advancing similar therapies.
- The overall market sentiment has been cautious, with broader economic factors influencing investor confidence in biotech stocks.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
RAPP Latest News
No recent news available for RAPP.
RAPP Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for RAPP.
Price Targets
Consensus target: $52.22
RAPP MoonshotScore
What does this score mean?
The MoonshotScore rates RAPP 0-100 on quantitative fundamentals — growth, financial health, valuation, momentum, and risk.
Leadership: Abraham N. Ceesay
CEO
Abraham N. Ceesay serves as the CEO of Rapport Therapeutics, bringing extensive experience in the biopharmaceutical industry. Prior to joining Rapport, Ceesay held leadership positions at various biotech companies, where he oversaw drug development programs and strategic initiatives. His background includes expertise in neuroscience and a track record of successfully advancing drug candidates through clinical trials. Ceesay holds advanced degrees in neuroscience and business administration.
Track Record: Under Ceesay's leadership, Rapport Therapeutics has focused on advancing its lead product candidate, RAP-219, through clinical development. He has overseen the expansion of the company's pipeline and the establishment of strategic partnerships. Ceesay has also been instrumental in securing funding for the company's research and development programs. He successfully led the company through its initial public offering.
What Investors Ask About Rapport Therapeutics (RAPP) — Healthcare
What does the AI Score mean for RAPP?
RAPP holds an AI Score of 24/100 (Grade: F). This is an educational research signal, not a buy or sell recommendation. Rapport Therapeutics is a clinical-stage biopharmaceutical company focused on developing small molecule medicines for central nervous system (CNS) disorders. Their lead candidate, RAP-219, targets …
What does Rapport Therapeutics, Inc. Common Stock do?
Rapport Therapeutics is a clinical-stage biopharmaceutical company dedicated to discovering and developing small molecule medicines for central nervous system (CNS) disorders. Their primary focus is on creating transformational therapies for patients suffering from neurological conditions. Their lead product candidate, RAP-219, is an investigational small molecule designed to treat focal epilepsy by targeting TARPy8-containing AMPARs. The company also has other programs in development, including RAP-199 and nicotinic acetylcholine receptor (nAChR) programs.
What do analysts say about RAPP stock?
Analyst coverage of Rapport Therapeutics is still emerging, given its recent IPO. Current sentiment reflects cautious optimism, driven by the potential of RAP-219 and the company's focus on CNS disorders. Key valuation metrics being monitored include the progress of clinical trials, potential market size for RAP-219, and the company's cash runway.
What are the main risks for RAPP?
As a clinical-stage biopharmaceutical company, Rapport Therapeutics faces significant risks inherent in drug development. The primary risk is the potential failure of clinical trials for its lead product candidates, which could significantly impact the company's value.
What are the key factors to evaluate for RAPP?
Rapport Therapeutics (RAPP) holds an AI score of 24/100 (low). Analysts target $52.22 (+9%). Rapport Therapeutics presents a notable research candidate within the biotechnology sector, driven by its focus on CNS disorders and its lead candidate, RAP-219. Not financial advice.
How frequently does RAPP data refresh on this page?
RAPP's price was last updated on Aug 21, 2026 and refreshes on page view during U.S. market hours — it is not a real-time exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven RAPP's recent stock price performance?
Rapport Therapeutics (RAPP) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Novel approach to targeting TARPy8-containing AMPARs for CNS disorders. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider RAPP overvalued or undervalued right now?
Rapport Therapeutics (RAPP) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Analysts target $52.22 (+9%) — near fair value. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
How do I research RAPP before investing?
Before investing in Rapport Therapeutics (RAPP), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on publicly available sources and may be subject to change.
- The analysis is for informational purposes only and does not constitute investment advice.